Details for New Drug Application (NDA): 020823
✉ Email this page to a colleague
The generic ingredient in EXELON is rivastigmine. There are thirty-two drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the rivastigmine profile page.
Summary for 020823
Tradename: | EXELON |
Applicant: | Novartis |
Ingredient: | rivastigmine tartrate |
Patents: | 0 |
Profile for product number 003
Active Rx/OTC/Discontinued: | DISCN | Dosage: | CAPSULE;ORAL | Strength | EQ 1.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
Approval Date: | Apr 21, 2000 | TE: | RLD: | Yes |
Profile for product number 004
Active Rx/OTC/Discontinued: | DISCN | Dosage: | CAPSULE;ORAL | Strength | EQ 3MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
Approval Date: | Apr 21, 2000 | TE: | RLD: | Yes |
Profile for product number 005
Active Rx/OTC/Discontinued: | DISCN | Dosage: | CAPSULE;ORAL | Strength | EQ 4.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
Approval Date: | Apr 21, 2000 | TE: | RLD: | Yes |
Expired US Patents for NDA 020823
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Novartis | EXELON | rivastigmine tartrate | CAPSULE;ORAL | 020823-003 | Apr 21, 2000 | ⤷ Sign Up | ⤷ Sign Up |
Novartis | EXELON | rivastigmine tartrate | CAPSULE;ORAL | 020823-004 | Apr 21, 2000 | ⤷ Sign Up | ⤷ Sign Up |
Novartis | EXELON | rivastigmine tartrate | CAPSULE;ORAL | 020823-005 | Apr 21, 2000 | ⤷ Sign Up | ⤷ Sign Up |
Novartis | EXELON | rivastigmine tartrate | CAPSULE;ORAL | 020823-006 | Apr 21, 2000 | ⤷ Sign Up | ⤷ Sign Up |
Novartis | EXELON | rivastigmine tartrate | CAPSULE;ORAL | 020823-006 | Apr 21, 2000 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription